Search
Betamethasone phosphate
go.drugbank.com/drugs/DB14669ApprovedVet approvedBetamethasone phosphate is a prodrug that is rapidly hydrolyzed, providing rapidly accessible betamethasone to agonize glucocorticoid receptors. Betamethasone provides greater anti-inflammatory activity than prednisolone with less sodium...
Categories: P-glycoprotein inducers, Cytochrome P-450 CYP3A InducersRemdesivir
go.drugbank.com/drugs/DB14761ApprovedInvestigationalSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress s...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDordaviprone
go.drugbank.com/drugs/DB14844ApprovedInvestigational[A274391] Dordaviprone has several modes of action, including the activation of mitochondrial caseinolytic protease P (ClpP), antagonism of the dopamine D2 receptor,[L53833] activation of Activating Transcription
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InducersRelacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigationalRelacorilant is a first-in-class, selective glucocorticoid receptor antagonist. Originally investigated to manage the metabolic and endocrinologic complications of hypercortisolism, such as Cushing’s syndrome, its clinical utility has pi...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 InducersDifamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigationalAtopic dermatitis is a chronic and fluctuating pruritic inflammatory skin condition characterized by pruritic eczema and is also marked by exacerbations and remissions. This skin disease occurs most frequently in children and can have an...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigationalAprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of macitentan. Approximately 10-15% of patients with hypertension have resistant hypertension, defin...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2C18 InhibitorsInavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigationalPIK3CA is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 Enzyme InducersXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigationalSchizophrenia is a complex disease involving a number of different neurotransmitters, including serotonin, dopamine, and acetylcholine. Positive symptoms (e.g. hallucinations, delusions) have traditionally been attributed to increased do...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesFezolinetant
go.drugbank.com/drugs/DB15669ApprovedInvestigationalVasomotor symptoms (VMS), more colloquially known as hot flashes or night sweats, are some of the most common symptoms in menopause. With a median duration of 7.4 years, vasomotor symptoms are also the most common reasons why women seek ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesIptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigationalIptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor B. Factor B is a positive regulato...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 Substrates